1Department of Neurological Surgery, University of California, San Francisco, California; and.
2Deparment of Neurological Surgery, Indiana University, Indianapolis, Indiana.
J Neurosurg. 2018 Jan;128(1):68-77. doi: 10.3171/2016.9.JNS16149. Epub 2017 Feb 24.
OBJECTIVE Common surgical treatments for trigeminal neuralgia (TN) include microvascular decompression (MVD), stereotactic radiosurgery (SRS), and radiofrequency ablation (RFA). Although the efficacy of each procedure has been described, few studies have directly compared these treatment modalities on pain control for TN. Using a large prospective longitudinal database, the authors aimed to 1) directly compare long-term pain control rates for first-time surgical treatments for idiopathic TN, and 2) identify predictors of pain control. METHODS The authors reviewed a prospectively collected database for all patients who underwent treatment for TN between 1997 and 2014 at the University of California, San Francisco. Standardized collection of data on preoperative clinical characteristics, surgical procedure, and postoperative outcomes was performed. Data analyses were limited to those patients who received a first-time procedure for treatment of idiopathic TN with > 1 year of follow-up. RESULTS Of 764 surgical procedures performed at the University of California, San Francisco, for TN (364 SRS, 316 MVD, and 84 RFA), 340 patients underwent first-time treatment for idiopathic TN (164 MVD, 168 SRS, and 8 RFA) and had > 1 year of follow-up. The analysis was restricted to patients who underwent MVD or SRS. Patients who received MVD were younger than those who underwent SRS (median age 63 vs 72 years, respectively; p < 0.001). The mean follow-up was 59 ± 35 months for MVD and 59 ± 45 months for SRS. Approximately 38% of patients who underwent MVD or SRS had > 5 years of follow-up (60 of 164 and 64 of 168 patients, respectively). Immediate or short-term (< 3 months) postoperative pain-free rates (Barrow Neurological Institute Pain Intensity score of I) were 96% for MVD and 75% for SRS. Percentages of patients with Barrow Neurological Institute Pain Intensity score of I at 1, 5, and 10 years after MVD were 83%, 61%, and 44%, and the corresponding percentages after SRS were 71%, 47%, and 27%, respectively. The median time to pain recurrence was 94 months (25th-75th quartiles: 57-131 months) for MVD and 53 months (25th-75th quartiles: 37-69 months) for SRS (p = 0.006). A subset of patients who had MVD also underwent partial sensory rhizotomy, usually in the setting of insignificant vascular compression. Compared with MVD alone, those who underwent MVD plus partial sensory rhizotomy had shorter pain-free intervals (median 45 months vs no median reached; p = 0.022). Multivariable regression demonstrated that shorter preoperative symptom duration (HR 1.005, 95% CI 1.001-1.008; p = 0.006) was associated with favorable outcome for MVD and that post-SRS sensory changes (HR 0.392, 95% CI 0.213-0.723; p = 0.003) were associated with favorable outcome for SRS. CONCLUSIONS In this longitudinal study, patients who received MVD had longer pain-free intervals compared with those who underwent SRS. For patients who received SRS, postoperative sensory change was predictive of favorable outcome. However, surgical decision making depends upon many factors. This information can help physicians counsel patients with idiopathic TN on treatment selection.
三叉神经痛(TN)的常见手术治疗方法包括微血管减压术(MVD)、立体定向放射外科手术(SRS)和射频消融术(RFA)。虽然每种手术的疗效都有描述,但很少有研究直接比较这些治疗方法对 TN 疼痛控制的效果。本研究使用大型前瞻性纵向数据库,旨在:1)直接比较首次手术治疗特发性 TN 的长期疼痛控制率;2)确定疼痛控制的预测因素。
作者回顾性分析了 1997 年至 2014 年期间在加利福尼亚大学旧金山分校接受治疗的所有 TN 患者的前瞻性收集数据库。对术前临床特征、手术程序和术后结果进行了标准化数据收集。数据分析仅限于接受首次治疗特发性 TN 的患者,随访时间超过 1 年。
在加利福尼亚大学旧金山分校进行的 764 例 TN 手术中(364 例 SRS、316 例 MVD 和 84 例 RFA),340 例患者接受了首次治疗特发性 TN(164 例 MVD、168 例 SRS 和 8 例 RFA),随访时间超过 1 年。分析仅限于接受 MVD 或 SRS 治疗的患者。接受 MVD 的患者比接受 SRS 的患者年轻(中位数年龄分别为 63 岁和 72 岁,p<0.001)。MVD 的平均随访时间为 59±35 个月,SRS 为 59±45 个月。大约 38%接受 MVD 或 SRS 治疗的患者有超过 5 年的随访(分别为 60 例和 64 例患者)。MVD 和 SRS 的即刻或短期(<3 个月)术后无疼痛率(巴罗神经研究所疼痛强度评分 I)分别为 96%和 75%。MVD 治疗后 1、5 和 10 年时巴罗神经研究所疼痛强度评分 I 的患者比例分别为 83%、61%和 44%,SRS 后分别为 71%、47%和 27%。MVD 的中位疼痛复发时间为 94 个月(25-75 分位:57-131 个月),SRS 为 53 个月(25-75 分位:37-69 个月)(p=0.006)。部分接受 MVD 治疗的患者还接受了部分感觉根切断术,通常在血管压迫不明显的情况下进行。与单独接受 MVD 治疗相比,同时接受 MVD 和部分感觉根切断术的患者无疼痛间隔更短(中位数为 45 个月,无中位数达到;p=0.022)。多变量回归显示,术前症状持续时间较短(HR 1.005,95%CI 1.001-1.008;p=0.006)与 MVD 治疗结果良好相关,而 SRS 后感觉变化(HR 0.392,95%CI 0.213-0.723;p=0.003)与 SRS 治疗结果良好相关。
在这项纵向研究中,接受 MVD 治疗的患者无疼痛间隔时间长于接受 SRS 治疗的患者。对于接受 SRS 治疗的患者,术后感觉变化是良好结果的预测因素。然而,手术决策取决于许多因素。这些信息可以帮助医生为特发性 TN 患者选择治疗方案。